Introduction Globally, depression affects millions of individuals. A third of depression patients meet the criteria for treatment-resistant depression (TRD). The N-methyl-D-aspartate receptor antagonist, ketamine, improved depressive symptoms in a span of 24-hours. Recently, the FDA approved esketamine, an enantiomer of ketamine for TRD. Objectives To determine the effectiveness of ketamine and...
European PsychiatryApril 1, 2021Mahwish Adnan, F. Motiwala, Zeeshan Mansuri et al.
Introduction The immediate antidepressant effect of Ketamine has become a breakthrough in the treatment of depression. Cytochrome CYP3A4 and 2B6 primarily metabolize Ketamine. Objectives The present study explores potential pharmacokinetic and pharmacodynamic interactions of Lamotrigine and Ketamine. Methods A literature search was conducted using (“ketamine” OR “Lamotrigine” AND Interactions...
The biochemical processes involved in depression go beyond serotonin, norepinephrine, and dopamine. The N-methyl-D-aspartate (NMDA) receptor has a major role in the neurophysiology of depression. Ketamine, one of the prototypical NMDA antagonists, works rapidly in controlling depressive symptoms, including acutely suicidal behavior, by just a single injection. Ketamine may rapidly increase the...